

# ESMO PRECEPTORSHIP PROGRAMME

## LYMPHOMA

Malignant lymphomas  
Modern classification and management of the most frequent entities

Lugano, Switzerland  
3-4 November 2017

### CO-CHAIRS:

Michele Ghielmini, Switzerland  
Martin Dreyling, Germany

### SPEAKERS:

Elias Campo, Spain  
Massimo Federico, Italy  
Martin Hutchings, Denmark  
Silvia Montoto, United Kingdom  
Leticia Quintanilla-Fend, Germany  
Lena Specht, Denmark

### LEARNING OBJECTIVES

- To highlight the pathological bases of the most recent lymphoma classification
- To understand the role of PET in staging, re-staging and follow-up
- To review the treatment strategy for the most common lymphoma types
- To dissect the peculiarities of lymphomas arising in particular extranodal sites
- To illustrate special and innovative treatment strategies
- To discuss clinical cases between faculty and participants

### Friday, 3 November 2017

|                     |                                                                  |                              |
|---------------------|------------------------------------------------------------------|------------------------------|
| 08:45-09:00<br>15'  | Opening and welcome                                              |                              |
| 15'                 | Welcome from ESMO, objectives and scientific introduction        | Michele Ghielmini, CH        |
| 09:00-10:40<br>100' | SESSION 1<br>Pathology and staging                               | Speakers                     |
| 30'                 | The history of lymphoma classification and the 2016 WHO revision | Elias Campo, ES              |
| 20'                 | Methods used to diagnose lymphoma                                | Leticia Quintanilla-Fend, DE |
| 20'                 | Role of PET in staging and treatment of lymphomas                | Martin Hutchings, DK         |
| 2x15'               | 2 x Participant clinical case discussion                         | Faculty                      |

Each 15 minute slot for clinical case discussion includes 7' case presentation plus 8' Q&A / panel discussion

|             |              |
|-------------|--------------|
| 10:40-11:10 | Coffee Break |
|-------------|--------------|

| <b>11:10-12:40<br/>90'</b> | <b>SESSION 2<br/>Indolent</b>                | <b>Speakers</b>       |
|----------------------------|----------------------------------------------|-----------------------|
| 20'                        | Pathology of the indolent lymphoid neoplasms | Elias Campo, ES       |
| 20'                        | Treatment of follicular lymphoma             | Michele Ghielmini, CH |
| 20'                        | Treatment of chronic lymphocytic leukemia    | Martin Dreyling, DE   |
| 2x15'                      | 2 x Participant clinical case discussion     | Faculty               |

Each 15 minute slot for clinical case discussion includes 7' case presentation plus 8' Q&A / panel discussion

|                    |              |
|--------------------|--------------|
| <b>12:40-14:00</b> | <b>Lunch</b> |
|--------------------|--------------|

| <b>14:00-15:30<br/>90'</b> | <b>SESSION 3<br/>Aggressive</b>          | <b>Speakers</b>              |
|----------------------------|------------------------------------------|------------------------------|
| 20'                        | Pathology of aggressive lymphomas        | Leticia Quintanilla-Fend, DE |
| 20'                        | Treatment of DLBCL                       | Michele Ghielmini, CH        |
| 20'                        | Lymphoma in HIV+ patients                | Silvia Montoto, UK           |
| 2x15'                      | 2 x Participant clinical case discussion | Faculty                      |

Each 15 minute slot for clinical case discussion includes 7' case presentation plus 8' Q&A / panel discussion

|                    |                     |
|--------------------|---------------------|
| <b>15:30-16:00</b> | <b>Coffee Break</b> |
|--------------------|---------------------|

| <b>16:00-17:30<br/>90'</b> | <b>SESSION 4<br/>Mantle cell and extranodal</b> | <b>Speakers</b>       |
|----------------------------|-------------------------------------------------|-----------------------|
| 20'                        | Management of mantle cell lymphoma              | Martin Dreyling, DE   |
| 20'                        | MALT lymphoma                                   | Silvia Montoto, UK    |
| 20'                        | CNS lymphoma                                    | Michele Ghielmini, CH |
| 2x15'                      | 2 x Participant clinical case discussion        | Faculty               |

Each 15 minute slot for clinical case discussion includes 7' case presentation plus 8' Q&A / panel discussion

| <b>17:30-18:00<br/>30'</b> | <b>SESSION 5<br/>Q&amp;A Session</b> | <b>All Faculty</b> |
|----------------------------|--------------------------------------|--------------------|
|----------------------------|--------------------------------------|--------------------|

|              |               |
|--------------|---------------|
| <b>19:30</b> | <b>Dinner</b> |
|--------------|---------------|

## Saturday, 4 November 2017

| 08:30-10:00<br>90' | SESSION 6<br>Hodgkin                               | Speakers             |
|--------------------|----------------------------------------------------|----------------------|
| 20'                | Treatment of early stage                           | Massimo Federico, IT |
| 20'                | Treatment of advanced stage                        | Martin Hutchings, DK |
| 20'                | Prevention and screening of long term side effects | Lena Specht, DK      |
| 2x15'              | 2 x Participant clinical case discussion           | Faculty              |

Each 15 minute slot for clinical case discussion includes 7' case presentation plus 8' Q&A / panel discussion.

|             |              |
|-------------|--------------|
| 10:00-10:30 | Coffee Break |
|-------------|--------------|

| 10:30-12:00<br>90' | SESSION 7<br>T-cell lymphomas and special treatments | Speakers             |
|--------------------|------------------------------------------------------|----------------------|
| 20'                | Systemic T-cell lymphomas                            | Massimo Federico, IT |
| 20'                | The role of radiotherapy in lymphoma in 2016         | Lena Specht, DK      |
| 20'                | New drugs for lymphoma                               | Martin Dreyling, DE  |
| 2x15'              | 2 x Participant clinical case discussion             | Faculty              |

Each 15 minute slot for clinical case discussion includes 7' case presentation plus 8' Q&A / panel discussion.

| 12:00-12:30<br>30' | SESSION 8<br>Q&A Session and closing remarks | All faculty |
|--------------------|----------------------------------------------|-------------|
|--------------------|----------------------------------------------|-------------|

|             |       |
|-------------|-------|
| 12:30-13:15 | Lunch |
|-------------|-------|